While one aspect of good therapeutic design directed at the Bcl-2 proteins appears to have taken shape and is yielding tangible effects against tumor progression and cancer in the form of BH3-mimetics [137], this review article does highlight a new avenue that could be explored as an alternative and more inclusive therapeutic design strategy. This evidence concerns the gene BCL2 and cancer.